Living in a neighborhood with fewer resources is linked to worsening physical function and daily life for people with MS aged 55 and older.
Researchers followed 1,456 people with MS aged over 55 for 3–5 years and looked at how neighborhood resources and race related to health changes. They used a measure called the Area Deprivation Index (ADI) — a higher ADI means the neighborhood has fewer resources like parks, clinics, or good housing. People from higher-ADI neighborhoods were more likely to get worse on hand movement tests and walking speed tests, and to report more trouble with social roles, feeling stigmatized, and fatigue. Black participants, on average, showed less worsening in social role problems and depression than White participants in this study. Overall, the study suggests neighborhood resources matter more than race for some worsening MS outcomes in this age group.
People with MS and their caregivers should pay attention because where you live — not just your biology — can affect how symptoms and function change over time. Think of neighborhood resources like tools in a toolbox: if your neighborhood has fewer tools (fewer clinics, less safe walking spaces, fewer social supports), it can be harder to manage MS symptoms and stay active. Healthcare providers and care planners should consider a patient’s neighborhood when making treatment and support plans, since extra help may be needed for people from deprived areas. Community groups and local officials can use this to argue for better services (like accessible clinics, safe sidewalks, or community programs) that help people with MS stay mobile and socially connected. Caregivers can use this knowledge to look for resources outside the neighborhood (support groups, transportation services, telehealth) to fill gaps.
This study followed people treated at large MS centers, so results might not apply to everyone with MS, especially those not seen at specialty centers. The study shows links (associations) but cannot prove that living in a deprived neighborhood causes the worsening — other unmeasured factors might contribute. Also, most participants were White and female, so findings about race should be interpreted carefully and may not reflect all racial or gender groups.
AI-generated summary — for informational purposes only, not medical advice
12/31/2026
Learn how certain gut bacteria can worsen MS symptoms and what this means for treatment and daily li
Read More5/1/2026
Study finds a brain‑seeking CD4 killer cell tied to MS and CMV exposure that may resist some treatme
Read More5/1/2026
Study finds CD29 marks blood B cells that can enter the brain and become antibody-producing cells in
Read More5/1/2026
Study finds early detection, lower spinal fluid virus, and PML‑IRIS relate to better 1‑year outcomes
Read More5/1/2026
A new blood test detects an antibody linked to MS and EBV, which may help predict or support early d
Read More5/1/2026
Study found fewer hospital diagnoses of antibody-positive autoimmune encephalitis during COVID-19, b
Read MoreWhether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.